Back to top

Image: Bigstock

Top Ranked Income Stocks to Buy for April 6th

Read MoreHide Full Article

Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 6th:

Enviva Partners, LP (EVA - Free Report) : This producer of utility-grade wood pellets has witnessed the Zacks Consensus Estimate for its current year earnings increasing 29% over the last 60 days.

This Zacks Rank #1 (Strong Buy) company has a dividend yield of 10%, compared with the industry average of 0%. Its five-year average dividend yield is 8.6%.

Enviva Partners, LP Dividend Yield (TTM)

Enviva Partners, LP Dividend Yield (TTM)

Enviva Partners, LP dividend-yield-ttm | Enviva Partners, LP Quote

New Residential Investment Corp. (NRZ - Free Report) : This real estate investment trust has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.4% over the last 60 days.

This Zacks Rank #1 company has a dividend yield of 60.1%, compared with the industry average of 14.9%. Its five-year average dividend yield is 12.4%.

Green Plains Partners LP (GPP - Free Report) : This provider of fuel storage and transportation services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.3% over the last 60 days.

This Zacks Rank #2 (Buy) company has a dividend yield of 34.6%, compared with the industry average of 0%. Its five-year average dividend yield is 10%.

Ellington Financial Inc. (EFC - Free Report) : This manager of financial assets has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.2% over the last 60 days.

This Zacks Rank #2 company has a dividend yield of 46.2%, compared with the industry average of 0%. Its five-year average dividend yield is 11.1%.

See the full list of top ranked stocks here.

Find more top income stocks with some of our great premium screens.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>